2023
CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people with HIV
Albalawi Y, Shull T, Virdi A, Subra C, Mitchell J, Slike B, Jian N, Krebs S, Sacdalan C, Ratnaratorn N, Hsu D, Phanuphak N, Spudich S, Trautmann L, Al-Harthi L. CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people with HIV. AIDS 2023, 38: 1-7. PMID: 37792358, PMCID: PMC10715695, DOI: 10.1097/qad.0000000000003743.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyT cellsWeeks 0CD4-CD8Cerebrospinal fluidImmune activationSoluble markersSuppressive combination antiretroviral therapyPeripheral blood T cellsNeuro-inflammatory markersSubset of CD8Anti-inflammatory propertiesBlood T cellsConfidence intervalsPlasma of peopleT-cell typeCART initiationCSF neopterinPlasma RANTESAntiretroviral therapyWeek 24IP-10IL-6Lumbar punctureIL-8
2020
Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection.
Kallianpur KJ, Jahanshad N, Sailasuta N, Benjapornpong K, Chan P, Pothisri M, Dumrongpisutikul N, Laws E, Ndhlovu LC, Clifford KM, Paul R, Jagodzinski L, Krebs S, Ananworanich J, Spudich S, Valcour V. Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. AIDS 2020, 34: 415-426. PMID: 31725432, PMCID: PMC6994348, DOI: 10.1097/qad.0000000000002436.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyRegional brain volumesBrain volumeSuppressive combination antiretroviral therapyBrain magnetic resonance imagingBrain volumetric changesAcute HIV infectionLongitudinal pipelineProspective cohort studyBrain metabolite levelsCerebrospinal fluid biomarkersVolumetric decreaseYears of treatmentMagnetic resonance imagingFreeSurfer longitudinal pipelineVoxel-wise analysisHigh baseline frequencyVolumes of putamenCART initiationHIV-1infectionProgressive HIVSimilar HIVAntiretroviral therapyCohort studyHIV exposure
2017
Neurological Complications of HIV Infection
Farhadian S, Patel P, Spudich S. Neurological Complications of HIV Infection. Current Infectious Disease Reports 2017, 19: 50. PMID: 29164407, PMCID: PMC7456329, DOI: 10.1007/s11908-017-0606-5.BooksCombination antiretroviral therapyHIV infectionSuppressive combination antiretroviral therapyChronic HIV infectionPathogenesis of HANDPurpose of ReviewHIVHIV-associated dementiaNeurofilament light chainAntiretroviral therapyCNS infectionNeurological complicationsNeurological outcomeHIV diseaseAsymptomatic individualsMonocyte activityBody of evidenceNeurocognitive disordersPreventive strategiesMultifactorial causesCellular injuryMild formInfectionHIVLight chainRecent studies
2016
Immune activation in the central nervous system throughout the course of HIV infection
Spudich SS. Immune activation in the central nervous system throughout the course of HIV infection. Current Opinion In HIV And AIDS 2016, 11: 226-233. PMID: 26760827, PMCID: PMC4773903, DOI: 10.1097/coh.0000000000000243.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyImmune activationAntiretroviral therapySuppressive combination antiretroviral therapyLong-term neurologic sequelaeCentral nervous system responseCNS immune activationFeatures of homeostasisPersistent immune activationBrain microglial cellsCervical lymph nodesCentral nervous systemSustained immune responseNervous system responsesImmune surveillance networkNeurologic sequelaeAcute infectionHIV infectionLymph nodesActivation associatesMicroglial cellsChronic infectionCNS cellsImmune responseCerebrospinal fluid
2006
Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and Failure
Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and Failure. The Journal Of Infectious Diseases 2006, 194: 1686-1696. PMID: 17109340, DOI: 10.1086/508750.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCSF HIV-1 RNA levelsPlasma HIV-1 RNA levelsRNA levelsAntiretroviral therapyCSF inflammationCopies/Successful therapyPlasma HIV-1 RNA assaysHIV-1 RNA assaysHIV-1-infected subjectsSuppressive combination antiretroviral therapyDrug resistanceHIV-1 levelsCombination antiretroviral therapyHIV-negative subjectsGenotypic resistance testingFailure of therapyHuman immunodeficiency virusCopies/mLSubset of subjectsActive neurological diseaseCross-sectional analysisVirological suppressionImmunodeficiency virus